What the FDA labels say about taking them together
Leflunomide and nateglinide
Leflunomide's FDA label of June 4, 2025 names nateglinide in its drug interactions section; the nateglinide label PlainMeds reads does not name leflunomide. The leflunomide label: “For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family, especially HMG-Co reductase inhibitors, consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of …”
Check it at the source: the leflunomide FDA label on DailyMed (effective June 4, 2025, sanofi-aventis U.S. LLC); the nateglinide FDA label on DailyMed (effective February 24, 2025, Strides Pharma Science Limited).
What does the leflunomide label say about nateglinide?
Leflunomide label, drug interactionsFor other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking ARAVA [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Arava), sanofi-aventis U.S. LLC, effective June 4, 2025 (SPL set 320f63f2-fac3-4aee-aff8-85724e00ef52), via openFDA; the full label on DailyMed
What does the nateglinide label say about leflunomide?
Nateglinide's label (effective February 24, 2025) does not name leflunomide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nateglinide), Strides Pharma Science Limited, effective February 24, 2025 (SPL set 0ccf9b07-3c21-482d-abeb-a06ceb482c7b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Leflunomide | Nateglinide | |
|---|---|---|
| Labeled for | Rheumatoid arthritis | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.324 per tablet 10 mg tablet | $0.179 per tablet 60 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once